{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:05:33Z","timestamp":1768453533444,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02489-0","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:57:56Z","timestamp":1746698276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation"],"prefix":"10.1007","volume":"16","author":[{"given":"Shirin","family":"Tavakoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Samareh-Salavatipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Mardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Salehi-Shadkami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Barkhordar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"1","key":"2489_CR1","first-page":"34","volume":"101","author":"WD Lewis","year":"2020","unstructured":"Lewis WD, Lilly S, Jones KL. Lymphoma: diagnosis and treatment. Am Fam Physician. 2020;101(1):34\u201341.","journal-title":"Am Fam Physician"},{"key":"2489_CR2","unstructured":"Jamil A, Mukkamalla S. Lymphoma. 2023."},{"issue":"6","key":"2489_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14656566.2020.1727445","volume":"21","author":"T Al-Juhaishi","year":"2020","unstructured":"Al-Juhaishi T, et al. Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020;21(6):653\u201361.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2489_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022;46(1): 100826.","journal-title":"Curr Probl Cancer"},{"issue":"10","key":"2489_CR5","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1007\/s12094-023-03153-1","volume":"25","author":"Y Che","year":"2023","unstructured":"Che Y, Sun X. Recent advances in CAR T-cell therapy for lymphoma in China. Clin Transl Oncol. 2023;25(10):2793\u2013800.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"2489_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck AV, et al. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28(4):678\u201389.","journal-title":"Nat Med"},{"issue":"3","key":"2489_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11864-021-00932-2","volume":"23","author":"Y Chu","year":"2022","unstructured":"Chu Y, et al. The future of natural killer cell immunotherapy for B cell non-Hodgkin lymphoma (B Cell NHL). Curr Treat Options Oncol. 2022;23(3):381\u2013403.","journal-title":"Curr Treat Options Oncol"},{"key":"2489_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.reth.2022.07.001","volume":"21","author":"T Nakazawa","year":"2022","unstructured":"Nakazawa T, et al. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors. Regener Ther. 2022;21:185\u201391.","journal-title":"Regener Ther"},{"issue":"4","key":"2489_CR9","doi-asserted-by":"publisher","first-page":"253.e1","DOI":"10.1016\/j.jtct.2022.12.025","volume":"29","author":"DH Yoon","year":"2023","unstructured":"Yoon DH, et al. Phase I study: safety and efficacy of an ex vivo-expanded allogeneic natural killer cell (MG4101) with rituximab for relapsed\/refractory B cell non-Hodgkin lymphoma. Transplant Cell Ther. 2023;29(4):253.e1-253.e9.","journal-title":"Transplant Cell Ther"},{"key":"2489_CR10","unstructured":"Bottino C, et al. Natural killer cells and engagers: powerful weapons against cancer. Immunol Rev."},{"key":"2489_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu W, et al. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10: 436512.","journal-title":"Front Immunol"},{"issue":"8","key":"2489_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/07357907.2018.1515315","volume":"36","author":"WC Suen","year":"2018","unstructured":"Suen WC, et al. Natural killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials. Cancer Invest. 2018;36(8):431\u201357.","journal-title":"Cancer Invest"},{"issue":"4","key":"2489_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F, et al. Advances in NK cell production. Cell Mol Immunol. 2022;19(4):460\u201381.","journal-title":"Cell Mol Immunol"},{"issue":"21","key":"2489_CR14","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.3390\/cells11213469","volume":"11","author":"LF Porrata","year":"2022","unstructured":"Porrata LF. Natural killer cells are key host immune effector cells affecting survival in autologous peripheral blood hematopoietic stem cell transplantation. Cells. 2022;11(21):3469.","journal-title":"Cells"},{"key":"2489_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40778-017-0106-4","volume":"3","author":"MA de Witte","year":"2017","unstructured":"de Witte MA, Kuball J, Miller JS. NK cells and \u03b3\u03b4T cells for relapse protection after allogeneic hematopoietic cell transplantation (HCT). Curr Stem Cell Rep. 2017;3:301\u201311.","journal-title":"Curr Stem Cell Rep"},{"key":"2489_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","volume":"8","author":"F Simonetta","year":"2017","unstructured":"Simonetta F, Alvarez M, Negrin RS. Natural killer cells in graft-versus-host-disease after allogeneic hematopoietic cell transplantation. Front Immunol. 2017;8:465.","journal-title":"Front Immunol"},{"issue":"6","key":"2489_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/JLB.MR0718-300R","volume":"105","author":"E Zaghi","year":"2019","unstructured":"Zaghi E, et al. Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. J Leukoc Biol. 2019;105(6):1243\u201351.","journal-title":"J Leukoc Biol"},{"key":"2489_CR18","unstructured":"Ke\u00dfler J. NK cells in tumor immune evasion: role of tumor-associated ligands that regulate NK cell function and therapeutical implications. Universit\u00e4t zu K\u00f6ln; 2012."},{"issue":"7","key":"2489_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbmt.2008.04.013","volume":"14","author":"LF Porrata","year":"2008","unstructured":"Porrata LF, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14(7):807\u201316.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2489_CR20","first-page":"73","volume":"214","author":"T Bryceson","year":"2006","unstructured":"Bryceson T, et al. Immunologic autograft engineering and survival in non-Hodgkin lymphoma. Immunol Res. 2006;214:73\u201391.","journal-title":"Immunol Res"},{"key":"2489_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF01910314","volume":"71","author":"D Raspadori","year":"1995","unstructured":"Raspadori D, et al. Low doses of rIL2 after autologous bone marrow transplantation induce a \u201cprolonged\u201d immunostimulation of NK compartment in high-grade non-Hodgkin\u2019s lymphomas. Ann Hematol. 1995;71:175\u20139.","journal-title":"Ann Hematol"},{"issue":"1","key":"2489_CR22","first-page":"34","volume":"3","author":"JS Miller","year":"1997","unstructured":"Miller JS, et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant. 1997;3(1):34\u201344.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3B","key":"2489_CR23","first-page":"1861","volume":"24","author":"E Ishikawa","year":"2004","unstructured":"Ishikawa E, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24(3B):1861\u201371.","journal-title":"Anticancer Res"},{"issue":"2","key":"2489_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/bmt.2017.225","volume":"53","author":"A Kansagra","year":"2018","unstructured":"Kansagra A, et al. Infusion of autograft natural killer cell\/CD14+ HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation. Bone Marrow Transplant. 2018;53(2):146\u201354.","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2489_CR25","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","volume":"17","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17(19):6287\u201397.","journal-title":"Clin Cancer Res"},{"key":"2489_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.02.002","author":"DA Knorr","year":"2014","unstructured":"Knorr DA, et al. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014. https:\/\/doi.org\/10.1016\/j.smim.2014.02.002.","journal-title":"Semin Immunol"},{"issue":"1","key":"2489_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2003-12-4438","volume":"104","author":"T Igarashi","year":"2004","unstructured":"Igarashi T, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104(1):170\u20137.","journal-title":"Blood"},{"issue":"7","key":"2489_CR28","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.3390\/ijms21072263","volume":"21","author":"F Sharifzad","year":"2020","unstructured":"Sharifzad F, et al. HSP70\/IL-2 treated NK cells effectively cross the blood brain barrier and target tumor cells in a rat model of induced glioblastoma multiforme (GBM). Int J Mol Sci. 2020;21(7):2263.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2489_CR29","doi-asserted-by":"publisher","first-page":"S474","DOI":"10.1016\/j.bbmt.2017.12.557","volume":"24","author":"AA Hamidieh","year":"2018","unstructured":"Hamidieh AA, et al. Natural killer cells treated with CD11b expressing subpopulation of exosomes show highly activated phenotype against neuroblastoma: a future prospect for the treatment of high-risk neuroblastoma. Biol Blood Marrow Transplant. 2018;24(3):S474.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2489_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29676","volume":"69","author":"M Behfar","year":"2022","unstructured":"Behfar M, et al. Adoptive NK-cell transfer as a potential treatment paradigm for Wilms tumor: a preclinical study. Pediatr Blood Cancer. 2022;69(8): e29676.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2489_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/2326-6066.CIR-15-0118","volume":"4","author":"Y Yang","year":"2016","unstructured":"Yang Y, et al. Phase I study of random healthy donor\u2013derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res. 2016;4(3):215\u201324.","journal-title":"Cancer Immunol Res"},{"key":"2489_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-142419","volume":"136","author":"V Bachanova","year":"2020","unstructured":"Bachanova V, et al. Results of a phase 1 trial of Gda-201, nicotinamide-expanded allogeneic natural killer (NK) Cells in patients with refractory non-hodgkin lymphoma (NHL) and multiple myeloma. Blood. 2020;136:6.","journal-title":"Blood"},{"issue":"1","key":"2489_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053611","volume":"8","author":"O Lim","year":"2013","unstructured":"Lim O, et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS ONE. 2013;8(1): e53611.","journal-title":"PLoS ONE"},{"issue":"3","key":"2489_CR34","first-page":"177","volume":"14","author":"V Swapna","year":"2018","unstructured":"Swapna V, Sudhakar V, Javerappa D. Study of liver function tests in breast carcinoma patients before and after chemotherapy. Int J Biotechnol Biochem. 2018;14(3):177\u201384.","journal-title":"Int J Biotechnol Biochem"},{"issue":"1","key":"2489_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","volume":"23","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, et al. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer. 2023;23(1):1090.","journal-title":"BMC Cancer"},{"issue":"1","key":"2489_CR36","doi-asserted-by":"publisher","first-page":"20971","DOI":"10.1038\/s41598-024-70958-7","volume":"14","author":"R Mohseni","year":"2024","unstructured":"Mohseni R, et al. Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed\/refractory neuroblastomas post autologous hematopoietic stem cell transplantation. Sci Rep. 2024;14(1):20971.","journal-title":"Sci Rep"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02489-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02489-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02489-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:58:00Z","timestamp":1746698280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02489-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02489-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Research and Ethics Committee of the Tehran University of Medical Sciences, and all experiments were performed in accordance with relevant guidelines and regulations (Approval No. IR.TUMS.MEDICINE.REC.1399.500). The participants or their legal guardian\/next of kin provided written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"694"}}